Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Other financing activities (2021 - 2025)

Historic Other financing activities for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to $137178.0.

  • InMed Pharmaceuticals' Other financing activities fell 2848.76% to $137178.0 in Q3 2025 from the same period last year, while for Dec 2025 it was $386634.0, marking a year-over-year increase of 4077.49%. This contributed to the annual value of $883978.0 for FY2025, which is 5724.92% up from last year.
  • According to the latest figures from Q3 2025, InMed Pharmaceuticals' Other financing activities is $137178.0, which was down 2848.76% from $57632.0 recorded in Q4 2024.
  • Over the past 5 years, InMed Pharmaceuticals' Other financing activities peaked at $1.1 million during Q3 2021, and registered a low of $25191.0 during Q3 2023.
  • Its 5-year average for Other financing activities is $351639.8, with a median of $185471.0 in 2021.
  • In the last 5 years, InMed Pharmaceuticals' Other financing activities plummeted by 9559.03% in 2023 and then skyrocketed by 66147.83% in 2024.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' Other financing activities stood at $179118.0 in 2021, then soared by 282.23% to $684650.0 in 2022, then crashed by 96.32% to $25191.0 in 2023, then skyrocketed by 128.78% to $57632.0 in 2024, then surged by 138.02% to $137178.0 in 2025.
  • Its last three reported values are $137178.0 in Q3 2025, $57632.0 for Q4 2024, and $191824.0 during Q3 2024.